Cantor Fitzgerald Reiterates Overweight on Neurocrine Biosciences, Maintains $155 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a price target of $155.
July 25, 2024 | 2:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a price target of $155.
The reiteration of an Overweight rating and a maintained price target of $155 by a reputable analyst can boost investor confidence in the short term, likely leading to a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100